Jerry Li

Jerry Li is a Researcher in the Division of Immunology and Infectious Diseases at The Australian National University. His work focuses on vaccine development, immune response mechanisms, and the interplay between innate immune cells (innate lymphoid cells and dendritic cells) and viral vector-based vaccines. He has contributed to studies on SARS-CoV-2 vaccines, adjuvant selection for influenza and RSV vaccines, and cytokine regulation in vaccination contexts.

Research interests include vaccination policy optimization, viral vector efficacy, and understanding how adjuvants modulate immune responses. His recent studies emphasize long-term vaccine safety, molecular clamp technologies for stable antigen presentation, and cytokine signaling pathways in vaccine-induced immunity.

Notable research trends include interdisciplinary approaches combining virology, immunology, and clinical trial outcomes. While no scientific awards are explicitly mentioned, his contributions to SARS-CoV-2 vaccine development have garnered significant citations. No specific grants or advising roles are detailed in the provided text.

Jerry Li collaborates with multidisciplinary teams, including researchers from clinical immunology, molecular virology, and translational medicine. His work aligns with broader efforts to combat emerging infectious diseases through advanced vaccine design and immune modulation strategies.